Loading
companiesCompany
Blue Earth Diagnostics (Bracco)
Blue Earth Diagnostics makes Posluma (18F-rhPSMA-7.3) and Axumin (fluciclovine) PET agents for prostate cancer.
Overview
Blue Earth Diagnostics, based in Oxford and a subsidiary of Bracco, makes the PET imaging agents Posluma, or flotufolastat F-18, also written 18F-rhPSMA-7.3, and Axumin, or fluciclovine F-18, for prostate cancer. Posluma was approved in 2023 on the LIGHTHOUSE and SPOTLIGHT trials, and a therapeutic rhPSMA analogue is in development, which would extend the radiohybrid platform from imaging into treatment. OnCo links it to prostate cancer and to both tracer records. Whether a fluorine-18 PSMA agent with a matched therapeutic can win share from the gallium-68 tracers already established is the open question. Flotufolastat and fluciclovine have their own pages.
Headquarters
Oxford, GB
Scorecard
All companies#169of 1244 companies, score 33
- approved products +12
- targets +2
- modalities +2
- regions +4
- registry trials +13
2 approved, 0 in phase 3, 0 earlier, 1 targets, 41 registry studies. Formula on the scorecards page.
Website
ApprovedPET imaging agent
Flotufolastat F-18 · Posluma
Flotufolastat is a third PSMA PET tracer, with a radiohybrid chemistry designed to be reused for therapy.
ApprovedPET radiotracer (synthetic amino acid)
Fluciclovine F-18 · Axumin
Fluciclovine F-18 was the first PET tracer approved for finding recurrent prostate cancer after treatment (2016), and has been largely superseded since 2020 by PSMA PET.
Similar pages
- TrialDiagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Shares Flotufolastat F-18, Prostate cancer.
- TrialPET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Shares Flotufolastat F-18, Prostate cancer.
- CompanyMedpace
Shares [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications, [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications.
- TrialAssessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Shares Flotufolastat F-18, Prostate cancer.
- TrialTreating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Shares Fluciclovine F-18, Prostate cancer.
- BiomarkerPSMA expression by PET (PSMA-positive)
Shares Flotufolastat F-18, Prostate cancer.
- TermBiochemical recurrence (BCR)
Shares Fluciclovine F-18, Prostate cancer.
cancers
fronts
drugs
ApprovedPET imaging agent
Flotufolastat F-18 · Posluma
ApprovedPET radiotracer (synthetic amino acid)
Fluciclovine F-18 · Axumin